Bicara Therapeutics' (NASDAQ:BCAX - Get Free Report) lock-up period will end on Wednesday, March 12th. Bicara Therapeutics had issued 17,500,000 shares in its public offering on September 13th. The total size of the offering was $315,000,000 based on an initial share price of $18.00. After the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.
Analyst Upgrades and Downgrades
Several equities research analysts have weighed in on the company. HC Wainwright upped their target price on Bicara Therapeutics from $42.00 to $45.00 and gave the stock a "buy" rating in a research note on Monday, January 27th. Wedbush reiterated an "outperform" rating and issued a $31.00 price target on shares of Bicara Therapeutics in a research note on Wednesday, February 12th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $41.20.
Get Our Latest Analysis on BCAX
Bicara Therapeutics Stock Performance
Shares of BCAX traded up $0.80 during trading hours on Friday, reaching $16.55. The stock had a trading volume of 704,038 shares, compared to its average volume of 375,026. Bicara Therapeutics has a 12 month low of $11.10 and a 12 month high of $28.09. The stock has a 50-day moving average price of $13.53.
Institutional Trading of Bicara Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the stock. Spire Wealth Management acquired a new stake in Bicara Therapeutics in the fourth quarter valued at $31,000. BNP Paribas Financial Markets acquired a new stake in Bicara Therapeutics in the fourth quarter valued at $32,000. Legal & General Group Plc acquired a new stake in Bicara Therapeutics in the fourth quarter valued at $33,000. Summit Investment Advisors Inc. acquired a new stake in Bicara Therapeutics in the fourth quarter valued at $35,000. Finally, Virtus ETF Advisers LLC acquired a new stake in Bicara Therapeutics in the fourth quarter valued at $69,000.
Bicara Therapeutics Company Profile
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Read More
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
